These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34475004)

  • 1. Epidemiological changes in cytomegalovirus end-organ diseases in a developed country: A nationwide, general-population-based study.
    Yoo SG; Han KD; Lee KH; Lim J; La Y; Kwon DE; Han SH
    J Microbiol Immunol Infect; 2022 Oct; 55(5):812-819. PubMed ID: 34475004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Incidence and Effect of Cytomegalovirus Disease on Mortality in Transplant Recipients and General Population: Real-world Nationwide Cohort Data.
    Han SH; Yoo SG; Do Han K; La Y; Kwon DE; Lee KH
    Int J Med Sci; 2021; 18(14):3333-3341. PubMed ID: 34400903
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of Cytomegalovirus Disease on New-Onset Type 2 Diabetes Mellitus: Population-Based Matched Case-Control Cohort Study.
    Yoo SG; Han KD; Lee KH; La Y; Kwon DE; Han SH
    Diabetes Metab J; 2019 Dec; 43(6):815-829. PubMed ID: 30688050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of post-treatment viral load of cytomegalovirus in patients with hematologic malignancies.
    Lu W; Chen HP; Chan YJ; Wang FD
    J Microbiol Immunol Infect; 2021 Apr; 54(2):245-252. PubMed ID: 31444112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between cytomegalovirus end-organ diseases and moderate-to-severe dementia: a population-based cohort study.
    Lee KH; Kwon DE; Do Han K; La Y; Han SH
    BMC Neurol; 2020 May; 20(1):216. PubMed ID: 32466754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cytomegalovirus End-Organ Disease with Stroke in People Living with HIV/AIDS: A Nationwide Population-Based Cohort Study.
    Yen YF; Jen I; Chen M; Chuang PH; Liu YL; Sharp GB; Chen YM
    PLoS One; 2016; 11(3):e0151684. PubMed ID: 26986005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation.
    Maertens J; Cordonnier C; Jaksch P; Poiré X; Uknis M; Wu J; Wijatyk A; Saliba F; Witzke O; Villano S
    N Engl J Med; 2019 Sep; 381(12):1136-1147. PubMed ID: 31532960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A
    BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation.
    Chen K; Cheng MP; Hammond SP; Einsele H; Marty FM
    Blood Adv; 2018 Aug; 2(16):2159-2175. PubMed ID: 30154125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cause of End-Stage Renal Disease Is Not a Risk Factor for Cytomegalovirus Infection After Kidney Transplant.
    Singh T; Peery S; Astor BC; Parajuli S; Djamali A; Panzer SE
    Transplant Proc; 2019; 51(6):1810-1815. PubMed ID: 31256873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral treatment of cytomegalovirus infection.
    Ahmed A
    Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects.
    Hebart H; Kanz L; Jahn G; Einsele H
    Drugs; 1998 Jan; 55(1):59-72. PubMed ID: 9463790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of recurrent cytomegalovirus infection on long-term survival in solid organ transplant recipients.
    Gardiner BJ; Chow JK; Brilleman SL; Peleg AY; Snydman DR
    Transpl Infect Dis; 2019 Dec; 21(6):e13189. PubMed ID: 31581352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
    Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey.
    Navarro D; San-Juan R; Manuel O; Giménez E; Fernández-Ruiz M; Hirsch HH; Grossi PA; Aguado JM;
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28859257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N; Winston DJ; Razonable RR; Lyon GM; Silveira FP; Wagener MM; Stevens-Ayers T; Edmison B; Boeckh M; Limaye AP
    JAMA; 2020 Apr; 323(14):1378-1387. PubMed ID: 32286644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.